Results 21 to 30 of about 179,682 (263)
Comparison of Adenosine Deaminase (ADA) and Cancer Antigen 125 (CA 125) Levels in Epithelial Ovarian Tumors [PDF]
, 2019 Introduction: In this study, we aimed to determine serum adenosine deaminase (ADA) and cancer antigen 125 (CA 125)levels in patients with epithelial ovarian tumors.Methods: A total of 75 patients with 47 malignant and 28 benign epithelial ovarian tumors ...
Korun, Zeynep Ece Utkan +6 more
core +1 more source
Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with gastric cancer (stage IA-IB). A case-control study. [PDF]
, 2016 Background: Gastric cancer (GC) is a rare malignancy in Western countries, accounting approximately for 1.5% of all cancers in the USA. However, worldwide, the expected new cases in 2015 were 630,000 and 320,000 among men and women, respectively, with ...
LUMACHI, FRANCO +4 more
core +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
PANoptosis in the pathogenesis of myelodysplastic syndromes
Molecular Oncology, EarlyView.PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source
Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors [PDF]
, 2000 Objectives. The goals of this study were to analyze preoperative serum levels of CA 125, carcinoembryonic antigen (CEA), and CA 19-9 in patients with borderline ovarian tumors and to investigate if routine assessment of these markers in follow-up may ...
van der Zee, AGJ +6 more
core +2 more sources
Advanced Healthcare Materials, EarlyView.Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj +23 more
wiley +1 more source
The Predictive Value of CA-125 and Hb for Ocular Metastasis in Hepatocellular Carcinoma Patients [PDF]
, 2022 Xin Xiong,1,* Rong Rong,2,* Li-Ying Tang,3,* Tie Sun,1 Yi-Cong Pan,1 Hui-Ye Shu,1 Li-Juan Zhang,1 Qian-Min Ge,1 Rong-Bin Liang,1 Yi Shao1 1Department of Pathology and Ophthalmology, The First Affiliated Hospital of Nanchang University ...
Pan YC +9 more
core
Advanced Healthcare Materials, EarlyView.Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave +8 more
wiley +1 more source
Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection [PDF]
, 2010 In previous studies we described the use of a retrospective collection of ovarian cancer and benign disease samples, in combination with a large set of multiplexed immunoassays and a multivariate pattern recognition algorithm, to develop an 11-biomarker ...
Brigitte E. Miller +20 more
core +1 more source
Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Advanced Materials, EarlyView.Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa +3 more
wiley +1 more source